iCell Hepatocytes 2.0, 01279

Kit Size

Catalog #: R1104
Catalog #: R1025

Cells Only

Catalog #: C1090
Catalog #: C1023
Catalog #: C1023

Hepatocytes 2.0 differentiated from human iPS cells, frozen

From
$595.00
Catalog # GHPC01279

Product Overview

The medical community needs a reproducible, well-characterized, and readily available source of human hepatocytes to advance signific tillitmatantly the launch of new metabolic and infectious disease therapies, reduce the incidence of drug-induced liver injury, and accelerate the development of novel approaches to liver regeneration and transplantation. To meet this need, CDI has leveraged iPS cell technology to develop iCell® Hepatocytes. These hepatocytes overcome the functionality, reproducibility, and availability limitations of existing primary cell and tumor-derived cell models by providing the following:
  • Relevant hepatic functionality and phenotypic stability
  • Expression of clinical targets that are relevant for liver and metabolic disease
  • Compatibility with a wide range of 3D and microphysiological systems
  • Quality-controlled manufacturing and batch reproducibility
  • Ready supply in a cryopreserved format

Proven Applications

iCell Hepatocytes 2.0 are being rapidly adopted for use in a wide range of applications:

Components:

Need Help With This Product?

Our specialists are here to help you find the best product for your application.

Our regular business hours are 9:00am to 5:00pm Central Time (USA)

Need Help With This Product?

Our specialists are here to help you find the best product for your application.

Our regular business hours are 9:00am to 5:00pm Central Time (USA)

Performance Data

iCell Hepatocytes 2.0 Morphology

The hepatocytes exhibit cobblestone morphology, round nuclei with distinct nucleoli, bi-nucleation (ovals), and formation of bile canaliculi (arrows).*

Figure 1:  iCell Hepatocytes 2.0 Show Characteristic Morphology

Figure 2: iCell Hepatocytes 2.0 Exhibit P450 Metabolism Activity

iCell Hepatocytes 2.0 Exhibit P450 Metabolism Activity

The hepatocytes exhibit robust (A) CYP3A basal activity and (B) CYP3A4 induction activity (response to rifampin measured by P450-Glo™ CYP3A4 Induction/Inhibition Assay, Promega Corp.).

Protein Expression

The hepatocytes exhibit expression of (A) alpha-1-antitrypsin and (B) albumin, (C) albumin production (measured by ELISA), (D) glycogen storage (measured by PAS staining), and lipid storage (data not shown).

Figure 3: iCell Hepatocytes 2.0 Exhibit Hepatocyte Protein Expression and Function

Figure 4: Phase Images of 2D and 3D Cultures of iCell Hepatocytes 2.0

3D Spheroid Formation

(A) Cells are thawed and plated into the collagen-coated cell culture plate to form a 2D confluent monolayer. (B) Cells are then detached and seeded in aULA plate to form 3D spheroids within 2 days. See the application protocol for details.

Product Highlights

Known genotype

iCell Hepatocytes 2.0 have been genotyped for 1,936 ADME markers in over 200 genes, including all FDA-validated genes and >90% of the ADME Core markers as defined by the PharmaADME group.

Functionally stable

iCell Hepatocytes 2.0 are platable and maintain hepatocyte functions in culture for at least one week.

Homogenous and reproducible

iCell Hepatocytes are >95% pure, providing biologically relevant and reproducible results.

Human cells

iCell Hepatocytes 2.0 are terminally differentiated from human iPS cells and exhibit hepatocyte characteristics and functions.

Publications